Clin2
NCT07411599Possibly a fitRecruiting

CAR-NK cell therapy plus cetuximab for belly-spread colorectal cancer

Colorectal CancerPeritoneal MetastasesCarcinomatosis

Treatments studied

Part of Cancer, Digestive system clinical trials.

This trial tests a new cell therapy (CAR-NK cells given directly into your belly and a vein) combined with a targeted drug (cetuximab) for colorectal cancer that has spread mainly to the lining of your belly. It aims to see if this treatment can shrink tumors and help people who have run out of standard chemotherapy options.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
28 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 or older.
  • Your cancer must be a type called microsatellite stable (MSS) and not have the BRAF V600E gene change.
  • Your tumor spread should mainly be in the lining of your belly, with no more than 8 small tumors elsewhere.
  • You must be willing to have a small surgery (diagnostic laparoscopy) to place a catheter in your belly for the treatment.
  • You must have adequate heart, kidney, liver, and blood function as checked by your doctor.
  • If you could become pregnant or father a child, you must agree to use effective birth control during the study and for 4 months after.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07589517Recruiting· Phase 1/Phase 2
CAR-NK Cell Therapy for Advanced Colorectal Cancer

This trial tests a new type of immune cell therapy (CAR-NK cells) designed to fight advanced colorectal cancer that has spread or cannot be surgically removed. The therapy is customized to target specific protein markers on your cancer cells.

Shenzhen, Guangdong
NCT05240950Recruiting· Phase 1
CAR-T cell therapy for colorectal cancer in the liver

This Phase 1 study tests an anti-CEA CAR-T cell treatment for people whose colorectal cancer spread to the liver but has been surgically removed with no visible remaining tumor. It aims to see if the treatment can better prevent the cancer from coming back, especially when early warning tests suggest leftover cancer cells.

Shanghai, Shanghai Municipality
NCT07509008Not yet recruiting· Phase 1/Phase 2
NK cell therapy for stomach cancer spread to abdomen

This trial tests a new kind of immune cell therapy (NK cells) designed to target and attack stomach cancer that has spread to the lining of the abdomen. It combines this with standard surgery and chemotherapy to see if it can help control the cancer.

Houston, Texas
NCT07462650Recruiting· Phase 1/Phase 2
CAR-NK cell therapy for advanced colorectal cancer

This trial tests a new treatment using modified natural killer cells (CAR-NK) that target two specific proteins found on your cancer cells. It is for people with advanced colorectal cancer who have tried standard treatments without success.

Shenzhen, Guangdong
NCT07021534Recruiting· Phase 1
CAR-NK and CAR-T cells for cancer with liver spread

This trial tests a new treatment that uses special immune cells (CAR-NK and CAR-T cells) given directly into the liver artery, then through a vein, to fight advanced solid tumors that have spread to the liver. It is for people who have already tried standard treatments and need new options.

Hangzhou, Zhejiang
NCT07247396Recruiting· Phase 1
CEA CAR-T therapy after surgery for colorectal cancer spread

This trial tests a special immune cell therapy (CAR-T) that targets a protein called CEA on cancer cells. It is for people with colorectal cancer that has spread to the lining of the belly (peritoneum) and who have already had surgery to remove as much of the spread as possible.

Hangzhou, Zhejiang

Hear when a new Colorectal cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.